Climb Bio Inc. has outlined its strategic priorities and future plans for 2026, focusing on advancing its clinical pipeline for immune-mediated diseases. The company expects initial data readouts from all ongoing trials of its two lead programs: budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody. Key upcoming activities include the release of initial data from a budoprutug subcutaneous formulation Phase 1 study in healthy volunteers and the dosing of the first patient in a China-based Phase 1b trial for systemic lupus erythematosus $(SLE)$, both anticipated in the first half of 2026. Climb Bio also plans to continue its clinical studies in primary membranous nephropathy (pMN), immune thrombocytopenia $(ITP)$, and SLE, with additional potential evaluation in lupus nephritis through a parallel China SLE trial. The company reports a strong financial position, with cash resources expected to fund operations into 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-006994), on January 08, 2026, and is solely responsible for the information contained therein.